Selected NAM Perspectives: The Regulatory Context

---

Recent discussions surrounding New Approach Methodologies (NAMs) increasingly extend beyond individual technologies to broader questions of translational decision-making, regulatory integration, and clinical development strategy. The selected reviews and perspectives below provide additional context on evolving safety assessment paradigms, limitations of traditional models, and emerging approaches to incorporating human-relevant evidence within drug development workflows.

Phelan, M. Existing NAMs May Already Cover Most Clinical Safety Risk. 

InnovApproach Consulting (February 24, 2026).
Link: https://innovapproach.com/2026/02/24/existing-nams-may-already-cover-most-clinical-safety-risk/ 

This commentary argues that a large fraction of clinical safety liabilities may already be addressable using existing NAM toolsets when deployed systematically (rather than as isolated point solutions). It frames the opportunity as one of coverage and integration—i.e., mapping known clinical risks to a portfolio of validated mechanistic assays and human-relevant systems. 

Phelan, M. Animal-Free Medicine: NAMs Are Powering Human Clinical Trials Without Animal Research. InnovApproach Consulting (December 16, 2025).
Link: https://innovapproach.com/2025/12/16/animal-free-medicine-nams-are-powering-human-clinical-trials-without-animal-research/ 

This article summarizes recent shifts in NAM policy and adoption and highlights public discussions of early clinical programs where NAM evidence may contribute to first-in-human decision-making. It emphasizes that “animal-free” isn’t a single technology claim, but typically a workflow-level choice, combining mechanistic assays, human-relevant systems, and structured risk justification. 

Reference: Van Norman, G.A. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? JACC: Basic to Translational Science (2019). DOI: 10.1016/j.jacbts.2019.10.008.

This landmark review critically examines why nonhuman animal studies often fail to predict human toxicity, highlighting biological species differences and limitations in translational validity. It sets up the rationale for greater use of human-relevant NAMs by arguing that current paradigms can generate false reassurance (or false risk) and contribute to costly late-stage failures.

Reference: Cook, D., Brown, D., Alexander, R. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery (2014). DOI: 10.1038/nrd4309. 

This influential and highly cited analysis proposes AstraZeneca’s “5R” framework (Right Target, Right Patient, Right Tissue, Right Safety, Right Commercial Potential) as a structured lens for improving R&D productivity and reducing late-stage attrition. It is often referenced in translational and regulatory strategy contexts because it frames development success as a function of fit-for-purpose evidence generation and decision quality.